2015/02/24

Canbex Therapeutics enters into option agreement with Ipsen

Paris (France) and London (United Kingdom), 24 February 2015 - Ipsen (Euronext: IPN; ADR: IPSEY) and Canbex Therapeutics Ltd (Canbex) today announced that Canbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as VSN16R.

Press Release

back to overview